Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

Business Wire July 5, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 1, 2022

Syros to Present at JMP Securities Life Sciences Conference

Business Wire June 8, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 3, 2022

Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Business Wire May 16, 2022

Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Business Wire May 9, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 29, 2022

Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022

Business Wire April 8, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 1, 2022

Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire March 15, 2022

Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022

Business Wire March 9, 2022

Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022

Business Wire March 8, 2022

Syros to Participate in Upcoming Virtual Investor Conferences in March

Business Wire February 28, 2022

Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS

Business Wire February 2, 2022

Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company

Business Wire January 10, 2022

Syros to Participate in Upcoming Investor Conferences

Business Wire November 16, 2021

Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire November 5, 2021

Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021

Business Wire October 29, 2021

Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 13, 2021

Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

Business Wire October 12, 2021